Combination pharmaceutical agents as inhibitors of hcv replication
AssigneeEnanta Pharmaceuticals, Inc.
InventorsYat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.
Claims36
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of a compound that inhibits the function of the HCV NS5A protein and an additional agent having anti-HCV activity.
A method of treating a patient suffering from a viral infection comprising administering to said patient a compound that inhibits the function of the HCV NS5A protein and an additional agent having anti-HCV activity.
25-37. (canceled)
The composition of claim 33, wherein the additional agent having anti-HCV activity inhibits the function of a target in the HCV life cycle other than the HCV NS5A protein.
48-75. (canceled)
Dependencies are inferred from the claim text.